US Bancorp’s Cidara Therapeutics CDTX Stock Holding History

US Bancorp’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24	Closed	-$5.3K	–	4192
2025 Q4	$5.3K	Buy	+24	New	+$3.88K	﹤0.01%	3510
2024 Q3	–	Sell	-13,103	Closed	-$156K	–	4097
2024 Q2	$156K	Sell	13,103 -1	-0%	-$14	﹤0.01%	2122
2024 Q1	$241K	Hold	13,104	–	–	﹤0.01%	1907
2023 Q4	$208K	Hold	13,104	–	–	﹤0.01%	1989
2023 Q3	$247K	Hold	13,104	–	–	﹤0.01%	1738
2023 Q2	$296K	Hold	13,104	–	–	﹤0.01%	1687
2023 Q1	$333K	Hold	13,104	–	–	﹤0.01%	1629
2022 Q4	$198K	Hold	13,104	–	–	﹤0.01%	1870
2022 Q3	$165K	Hold	13,104	–	–	﹤0.01%	1948
2022 Q2	$128K	Buy	+13,104	New	+$162K	﹤0.01%	2105

US Bancorp's CDTX Position: Q1 2026 in Review

US Bancorp sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 24 shares — an estimated $5.3K sold.

US Bancorp first reported a position in CDTX in Q2 2022 and held it in 10 quarters. The position peaked at $333K in Q1 2023. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

US Bancorp reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
US Bancorp sold 24 Cidara Therapeutics shares in Q1 2026, an estimated $5.3K.
US Bancorp first reported a position in Cidara Therapeutics in Q2 2022 and held it in 10 quarters.
US Bancorp's Cidara Therapeutics position peaked at $333K in Q1 2023.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.